small molecule

WIDAPLIK

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

Loss of exclusivityJanuary 2038latest FDA-listed patent expiry

CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	WIDAPLIK
Active ingredient	AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN
Strength	EQ 2.5MG BASE;1.25MG;20MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 2025
Marketing status	DISCN

Listed patents

Patent	Expires	Type
10799487	January 2038	product
12465599	January 2038	product

Regulatory exclusivity

Code	Expires
NP	June 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Azurity Pharmaceuticals